The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Boston Scientific Corp. (NYSE: BSX) was $76.01 for the day, down -0.71% from the previous closing price of $76.55. In other words, the price has decreased by -$0.71 from its previous closing price. On the day, 2.14 million shares were traded. BSX stock price reached its highest trading level at $77.0 during the session, while it also had its lowest trading level at $75.71.
Ratios:
Our analysis of BSX’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 46.14 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 65.81. For the most recent quarter (mrq), Quick Ratio is recorded 1.14 and its Current Ratio is at 1.66. In the meantime, Its Debt-to-Equity ratio is 0.55 whereas as Long-Term Debt/Eq ratio is at 0.50.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on May 30, 2024, initiated with a Buy rating and assigned the stock a target price of $90.
On February 01, 2024, Mizuho Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $65 to $80.
On July 19, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $59.Robert W. Baird initiated its Outperform rating on July 19, 2023, with a $59 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 01 ’24 when Carruthers Wendy sold 6,983 shares for $77.30 per share. The transaction valued at 539,786 led to the insider holds 42,908 shares of the business.
Carruthers Wendy sold 6,983 shares of BSX for $526,029 on Jun 03 ’24. The EVP, Human Resources now owns 45,628 shares after completing the transaction at $75.33 per share. On May 29 ’24, another insider, Mirviss Jeffrey B., who serves as the EVP&Pres, Periph Intervent of the company, sold 63,802 shares for $75.10 each. As a result, the insider received 4,791,447 and left with 28,022 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BSX now has a Market Capitalization of 111895396352 and an Enterprise Value of 120809390080. As of this moment, Boston’s Price-to-Earnings (P/E) ratio for their current fiscal year is 63.51, and their Forward P/E ratio for the next fiscal year is 28.73. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 5.12. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.60 while its Price-to-Book (P/B) ratio in mrq is 5.61. Its current Enterprise Value per Revenue stands at 8.214 whereas that against EBITDA is 32.285.
Stock Price History:
The Beta on a monthly basis for BSX is 0.79, which has changed by 0.43929648 over the last 52 weeks, in comparison to a change of 0.25510752 over the same period for the S&P500. Over the past 52 weeks, BSX has reached a high of $77.99, while it has fallen to a 52-week low of $48.35. The 50-Day Moving Average of the stock is 1.53%, while the 200-Day Moving Average is calculated to be 20.32%.
Shares Statistics:
BSX traded an average of 6.07M shares per day over the past three months and 5812140 shares per day over the past ten days. A total of 1.47B shares are outstanding, with a floating share count of 1.46B. Insiders hold about 0.45% of the company’s shares, while institutions hold 91.66% stake in the company. Shares short for BSX as of 1718323200 were 11539004 with a Short Ratio of 1.90, compared to 1715731200 on 12326651. Therefore, it implies a Short% of Shares Outstanding of 11539004 and a Short% of Float of 0.7900001.
Earnings Estimates
Boston Scientific Corp. (BSX) is currently under the scrutiny of 27.0 analysts, each contributing to the ongoing evaluation of its stock.On average, analysts expect EPS of $0.58 for the current quarter, with a high estimate of $0.59 and a low estimate of $0.57, while EPS last year was $0.53. The consensus estimate for the next quarter is $0.57, with high estimates of $0.61 and low estimates of $0.55.
Analysts are recommending an EPS of between $2.41 and $2.3 for the fiscal current year, implying an average EPS of $2.33. EPS for the following year is $2.64, with 31.0 analysts recommending between $2.79 and $2.55.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 21 analysts. It ranges from a high estimate of $4.07B to a low estimate of $3.97B. As of the current estimate, Boston Scientific Corp.’s year-ago sales were $3.6BFor the next quarter, 21 analysts are estimating revenue of $3.96B. There is a high estimate of $4.05B for the next quarter, whereas the lowest estimate is $3.9B.
A total of 31 analysts have provided revenue estimates for BSX’s current fiscal year. The highest revenue estimate was $16.25B, while the lowest revenue estimate was $15.82B, resulting in an average revenue estimate of $16B. In the same quarter a year ago, actual revenue was $14.24BBased on 31 analysts’ estimates, the company’s revenue will be $17.63B in the next fiscal year. The high estimate is $18.37B and the low estimate is $17.21B.
